In Vivo Therapy of the BCL1 Tumor: Effect of Immunotoxin Valency and Deglycosylation of the Ricin a Chain

R. J. Fulton, J. W. Uhr, E. S. Vitetta

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


The in vivo therapeutic effects of Fab' and IgG anti-δ (anti-IgD)-ricin A chain immunotoxins were compared in mice bearing the surface IgD-positive BCL1 leukemia. The immunotoxins were prepared with either native or deglycosylated ricin A chain. Immunotoxin therapy was assessed both by the number of cells bearing the BCL1 immunoglobulin idiotype which remained in the spleen 24–48 h after injection with immunotoxin and by adoptive transfer of these spleen cells into normal mice. Immunotoxins prepared with either Fab'-anti-δ or IgG-anti-δ and native A chain induced a dose-dependent reduction in the number of idiotype-positive BCL1 cells present in the spleens of the tumor-bearing mice. The maximal therapeutic response was achieved with 250 μg of immunotoxin (containing 80–100 μg A chain) per mouse for both immunotoxins, resulting in tumor reduction of approximately 90%. This represents an elimination of 3–4 x 10s tumor cells. Reduction in the number of tumor cells was not observed with control reagents including antibody alone, antibody mixed with A chain, or an immunotoxin of irrelevant specificity. A Fab' immunotoxin prepared with deglycosylated ricin A chain was approximately 5-fold more effective as an antitumor reagent than the same immunotoxin prepared with native A chain; thus, optimal therapy was achieved after injection of 50 μg of immunotoxin (containing 15–20 Mg A chain). Since the immunotoxins prepared with deglycosylated A chain were only 2-3-fold more toxic to the mice than those prepared with native A chain, the former resulted in a 2-3-fold increase in the therapeutic index.

Original languageEnglish (US)
Pages (from-to)2626-2631
Number of pages6
JournalCancer research
Issue number9
StatePublished - May 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'In Vivo Therapy of the BCL1 Tumor: Effect of Immunotoxin Valency and Deglycosylation of the Ricin a Chain'. Together they form a unique fingerprint.

Cite this